312 filings
8-K
TOVX
Theriva Biologics Inc
23 Apr 24
Regulation FD Disclosure
7:00am
8-K
TOVX
Theriva Biologics Inc
22 Apr 24
Regulation FD Disclosure
4:36pm
8-K
TOVX
Theriva Biologics Inc
16 Apr 24
Regulation FD Disclosure
8:00am
8-K
TOVX
Theriva Biologics Inc
25 Mar 24
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
7:40am
8-K
TOVX
Theriva Biologics Inc
7 Feb 24
Regulation FD Disclosure
8:10am
8-K
8j65wnui4h34 c4ea
8 Jan 24
Regulation FD Disclosure
8:10am
8-K
cum6fpk
13 Nov 23
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
8:10am
8-K
5gqpwrgsd6l1dnugms
23 Oct 23
Regulation FD Disclosure
7:10am
8-K
5sc0vt
17 Oct 23
Regulation FD Disclosure
6:05am
8-K
a64kuoazz261
3 Oct 23
Submission of Matters to a Vote of Security Holders
6:06am
8-K
j3nqflqxt
11 Aug 23
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
oox187y
8 Aug 23
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
8:10am
8-K
k5b9xt v2falwv0pm0t
2 Aug 23
Regulation FD Disclosure
9:22am
8-K
xi8g1q tot
27 Jun 23
Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer
5:11pm
8-K
12bvad r2wl6z8bxkwd
11 May 23
Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results
8:10am
8-K
6k3y0p6t4 7t
30 Mar 23
Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
8:15am
8-K
qam9bhu8wds6sq
10 Mar 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
5:01pm
8-K
mzqvn4e
16 Feb 23
Regulation FD Disclosure
4:09pm
8-K
btouohf
17 Jan 23
Regulation FD Disclosure
8:10am
8-K
t1feehij
9 Jan 23
Regulation FD Disclosure
8:10am